Short answer
Evolus, Inc. (EOLS) filed an 8-K current report with the SEC on July 8, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Exclusive U.S. license for Profhilo® aesthetics and dermatology applications, expanding Evolus beyond its existing product portfolio.
Evolus, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Exclusive U.S. license for Profhilo® aesthetics and dermatology applications, expanding Evolus beyond its existing product portfolio
- Evolus funds U.S. development, clinical trials and FDA approval, creating regulatory and commercialization costs
- No upfront or milestone payments, reducing near-term cash burden
- Fifteen-year initial term beginning at first FDA approval, with successive five-year renewal options
- Minimum purchases begin in commercial year four, with potential exclusivity loss or termination if requirements are unmet
Item 7.01 · Regulation FD Disclosure
- Evolus announced execution of an Agreement on July 8, 2026
- Exhibit 99.1 contains the related press release and substantive deal details
- Regulation FD filing makes the announcement publicly available to all investors simultaneously
Item EX-99.1 · Exhibit EX-99.1
- Exclusive U.S. license with IBSA adds Profhilo, expanding Evolus beyond neurotoxins and fillers into skin-quality injectables
- Profhilo has generated over 4.8 million treatments across more than 70 countries since its 2015 launch
- Evolus assumes U.S. development and commercialization responsibilities, creating regulatory execution and launch risk
- No upfront payment and transfer-price economics support a capital-efficient entry with targeted gross margins
- Agreement leaves 2026 revenue, operating expense, operating profit outlooks and 2028 targets unchanged
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Evolus, Inc. 8-K filings
Get the next EOLS 8-K as it lands
Follow EOLS for push alerts, or ask the research agent what this filing means.